1471 related articles for article (PubMed ID: 25773826)
1. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients.
Mansour A; Mohajeri-Tehrani MR; Samadi M; Gerami H; Qorbani M; Bellissimo N; Poustchi H; Hekmatdoost A
Acta Diabetol; 2019 Nov; 56(11):1199-1207. PubMed ID: 31197470
[TBL] [Abstract][Full Text] [Related]
4. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
[TBL] [Abstract][Full Text] [Related]
5. A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease.
Casey SP; Kemp WW; McLean CA; Topliss DJ; Adams LA; Roberts SK
Scand J Gastroenterol; 2012 Jul; 47(7):836-41. PubMed ID: 22519948
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors.
Prasetya IB; Hasan I; Wisnu W; Rumende CM
Acta Med Indones; 2017 Apr; 49(2):91-98. PubMed ID: 28790222
[TBL] [Abstract][Full Text] [Related]
7. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening.
Poustchi H; Alaei-Shahmiri F; Aghili R; Nobarani S; Malek M; Khamseh ME
Arch Iran Med; 2021 Mar; 24(3):177-186. PubMed ID: 33878875
[TBL] [Abstract][Full Text] [Related]
9. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.
Kwok R; Choi KC; Wong GL; Zhang Y; Chan HL; Luk AO; Shu SS; Chan AW; Yeung MW; Chan JC; Kong AP; Wong VW
Gut; 2016 Aug; 65(8):1359-68. PubMed ID: 25873639
[TBL] [Abstract][Full Text] [Related]
10. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
[TBL] [Abstract][Full Text] [Related]
12. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients.
Singh A; Le P; Peerzada MM; Lopez R; Alkhouri N
J Clin Gastroenterol; 2018 Mar; 52(3):268-272. PubMed ID: 28787358
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis.
Kwon YD; Ko KO; Lim JW; Cheon EJ; Song YH; Yoon JM
J Korean Med Sci; 2019 Jun; 34(23):e165. PubMed ID: 31197983
[TBL] [Abstract][Full Text] [Related]
14. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
[TBL] [Abstract][Full Text] [Related]
15. Liver Stiffness Measurement in Psoriasis: Do Metabolic or Disease Factors Play the Important Role?
Pongpit J; Porntharukchareon S; Kaewduang P; Promson K; Stitchantrakul W; Petraksa S; Thakkinstian A; Kositchaiwat C; Rajatanavin N; Sobhonslidsuk A
Biomed Res Int; 2016; 2016():7963972. PubMed ID: 27006950
[TBL] [Abstract][Full Text] [Related]
16. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
18. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors.
Lombardi R; Mantovani A; Cespiati A; Francione P; Maffi G; Del Zanna E; Maffeis C; Colecchia A; Passigato N; Ferrarese A; Cusumanu CD; Villani R; Orsi E; Grancini V; Airaghi L; Bignamini D; Serviddio G; Targher G; Dongiovanni P; Fargion S; Fracanzani AL
Dig Liver Dis; 2024 Apr; 56(4):551-558. PubMed ID: 37845152
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
[TBL] [Abstract][Full Text] [Related]
20. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]